The European Commission has approved RINVOQ (upadacitinib) for treating severe alopecia areata in adults and adolescents 12 years and older, based on Phase 3 clinical trials demonstrating significant scalp hair regrowth and improvements in eyebrows and eyelashes after 24 weeks. This marks RINVOQ as the first JAK inhibitor to achieve complete scalp hair regrowth compared to placebo. The approval offers a new treatment option for patients facing the physical and psychological burdens of this autoimmune disease. AbbVie continues to study RINVOQ for other immune-mediated conditions and is seeking FDA approval for alopecia areata in the U.S.
The European Commission has approved RINVOQ (upadacitinib) for treating non-segmental vitiligo (NSV) in adults and adolescents aged 12 and older. This marks the first systemic medication authorized in the EU for NSV, the most common form of vitiligo,...
US stock futures point to a strong start with Dow Jones up 1.1%, S&P 500 up 0.9%, and Nasdaq up 1.5%, driven by a sharp 6.3% drop in oil prices following a pause in US-Iran military actions. Although no official ceasefire is declared, Iran has agreed...
